Back to Search Start Over

An Access-Focused Patient-Centric Value Assessment Framework for Medication Formulary Decision-Making in Immune-Mediated Inflammatory Diseases.

Authors :
Yang, Min
Mittal, Manish
Fendrick, A. Mark
Brixner, Diana
Sherman, Bruce W.
Liu, Yifei
Patel, Pankaj
Clewell, Jerry
Liu, Qing
Garrison Jr., Louis P.
Source :
Advances in Therapy; Feb2025, Vol. 42 Issue 2, p568-578, 11p
Publication Year :
2025

Abstract

The healthcare system in the United States (US) is complex and often fragmented across national and regional health plans which exhibit substantial variability in benefit design and formulary policies for accessing medications. We propose an access-focused value assessment framework for formulary decision-making for medications to manage immune-mediated inflammatory diseases (IMIDs), where patients are at the center of this framework. Formulary decision-making for IMID medications can be a challenging, even daunting, task with continuously evolving and enhanced treat-to-target goals. Given the complexity of the US healthcare system, patients and their caregivers need assurance from formulary decision-makers that rapid, predictable, and sustained access to both well-established treatments and innovative therapies will be a priority, with a particular emphasis on continuity of effective care. This access-focused patient-centric (APAC) value assessment approach encompasses three "value components"—higher therapeutic goals, better health-related quality of life, and improved work productivity—the monetization of which can be derived using data from clinical trials when real-world data are yet to become available. Measures and assessment approaches are outlined to serve as a pragmatic tool for decision-makers in the US to ensure timely delivery and sustained access of clinically indicated therapies aimed to improve patient outcomes, enhance equity, and increase efficiency. Plain Language Summary: Formulary decision-making for immune-mediated inflammatory diseases can be complex, as more advanced therapies are developed and approved for multiple diseases, where clinical trial endpoints may vary substantially. We introduce an access-focused patient-centric framework as a decision tool maximizing patient centricity. It focuses on improvements in three core components: therapeutic outcomes, quality of life, and work productivity. Monetization of these components provides a common metric for payers to make informed decisions, allowing timely access for patients. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
0741238X
Volume :
42
Issue :
2
Database :
Complementary Index
Journal :
Advances in Therapy
Publication Type :
Academic Journal
Accession number :
182613924
Full Text :
https://doi.org/10.1007/s12325-024-03076-5